GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » Accounts Receivable

BioVaxys Technology (XCNQ:BIOV) Accounts Receivable : C$0.00 Mil (As of Jul. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. BioVaxys Technology's accounts receivables for the quarter that ended in Jul. 2024 was C$0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. BioVaxys Technology's Net-Net Working Capital per share for the quarter that ended in Jul. 2024 was C$-0.01.


BioVaxys Technology Accounts Receivable Historical Data

The historical data trend for BioVaxys Technology's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Accounts Receivable Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Accounts Receivable
Get a 7-Day Free Trial - - - - -

BioVaxys Technology Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioVaxys Technology Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


BioVaxys Technology Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

BioVaxys Technology's Days Sales Outstanding for the quarter that ended in Jul. 2024 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), BioVaxys Technology's accounts receivable are only considered to be worth 75% of book value:

BioVaxys Technology's Net-Net Working Capital Per Share for the quarter that ended in Jul. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.491+0.75 * 0+0.5 * 0-2.657
-0-0)/241.914
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


BioVaxys Technology Accounts Receivable Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
Executives
James Passin Director, Senior Officer
Kenneth Kovan Senior Officer

BioVaxys Technology Headlines

No Headlines